LC-MS: how a lab confirms a peptide is the one on the label.

Liquid chromatography separates a sample and mass spectrometry weighs what comes off the column: how that confirms a peptide's identity, how it differs from HPLC purity, and what mass alone cannot tell you.

Basics7 min read

Key takeaway

HPLC with a UV detector reports how much of the sample sits in the main peak: purity. Mass spectrometry compares the mass of that molecule with the mass calculated from the peptide’s formula: identity. ICH Q6A says a single chromatographic retention time is not specific enough for identification and names HPLC/MS as an acceptable combined test. Mass has limits too: it cannot tell leucine from isoleucine, or a D-amino acid from its L form.

At a glance

Article typeBasics
TopicTesting & quality
Studies cited5
Related productsResearch peptide catalog

LC-MS stands for liquid chromatography–mass spectrometry. It joins an instrument that separates a sample with one that weighs each part. For a research peptide, that weighing is how a lab confirms the vial holds the molecule on the label. This guide covers what LC-MS measures, how it differs from HPLC, what mass alone cannot tell you, and what the identity line on a certificate should show.

Quick answer: LC-MS is liquid chromatography coupled to a mass spectrometer. The liquid chromatograph separates the sample. The mass spectrometer turns each component into ions and sorts them by mass-to-charge ratio (m/z). For a peptide, the lab compares the observed mass with the theoretical mass of the expected sequence. A match confirms identity. HPLC purity alone cannot do that, because a wrong peptide can still give one clean, dominant peak.

What is LC-MS?

The United States Pharmacopeia defines mass spectrometry in general chapter <736> as an analytical technique based on measuring the mass-to-charge ratio of ions related to the analyte. Thermo Fisher’s overview describes the hardware in one line: every mass spectrometer has an ion source, a mass analyzer and an ion detector.

In LC-MS, components leave the column one after another and flow straight into the ion source, so each is measured as it elutes. Thermo Fisher notes that electrospray ionization (ESI) is the source most commonly used. Agilent’s LC/MS primer calls molecular weight determination a fundamental use of LC-MS and says that information is key to determining identity.

What is HPLC, briefly?

HPLC is high-performance liquid chromatography. USP chapter <621> describes chromatography as separating a sample’s parts between two phases. For peptides the detector is usually UV, and it draws a chromatogram: signal against time, one peak per component.

Purity is read from that trace. A review of peptide reference standards by USP and MHRA scientists reports chromatographic impurities as a percentage of the total detected peak area, the area-% convention. Our HPLC purity guide covers the details. The point here: a UV trace records how much material comes off the column and when, not what it is.

How mass spectrometry confirms identity

A peptide’s sequence fixes its chemical formula, and the formula fixes its mass. That calculated value is the theoretical mass. The lab measures the observed mass and compares the two. The USP review notes that mass spectrometry is often used to determine a peptide’s monoisotopic mass, and it reports theoretical values on that basis.

How close is close enough? It depends on the instrument and the method. In a 2014 BioPharm International article on peptide quality control, Verlander and Rode describe identity by mass spectrometry as determining the monoisotopic mass, which should be within ±1.0 mass units of theoretical. They add that for peptides larger than 2 kDa, high-resolution instruments may be necessary. A certificate should state which criterion the lab applied.

Charge states, in plain terms

A mass spectrometer weighs ions and reports mass divided by charge. Electrospray often gives a peptide more than one charge. Fenn and colleagues, in a 1989 Science paper on electrospray for large biomolecules, described spectra made of coherent sequences of peaks whose ions are multiply charged, each peak differing by one charge from its neighbors.

The Agilent primer gives the arithmetic with a simple example: a 100,000 u molecule carrying 10 charges appears at m/z 1,000. So one peptide can show up as several peaks, one per charge state. Software works back from those peaks to a single molecular mass, a step the primer calls deconvolution. A certificate that lists an observed m/z should also state the charge, or give the deconvoluted mass.

Why HPLC purity alone can’t prove identity

Purity answers “how much of this sample is the main component?”, not “is it the right molecule?” A synthesis that made the wrong sequence cleanly could still show one large peak and a high area-%.

Regulators address this directly. ICH Q6A, the international guideline on specifications, says identification tests should be specific, and that identification solely by a single chromatographic retention time is not regarded as specific. It accepts a combined procedure such as HPLC/MS, and notes that it may apply to synthetic peptides of low molecular weight. Verlander and Rode add that HPLC identity means comparing retention times with a reference standard, and that a single method is rarely unequivocal.

What mass alone can’t tell you

Mass has blind spots. Verlander and Rode state that mass spectrometry cannot distinguish isomers, such as isoleucine and leucine, or D- and L-amino acid substitutions. These swaps leave the formula, and so the mass, unchanged.

That matters because synthesis can create exactly these variants. A review of impurities in peptide medicines by D’Hondt and colleagues reports that the Fmoc-deprotection step can cause racemization of amino acid residues, giving diastereomeric impurities. The USP review says chiral or isobaric amino acids may need additional techniques for full characterization. Its toolkit includes tandem mass spectrometry (LC-MS/MS) to confirm sequence, amino acid analysis to tell leucine from isoleucine, and chiral testing for D-amino acids. Thermo Fisher notes that MS/MS is commonly used to sequence proteins.

Table 1

HPLC-UV and LC-MS, side by side

Attribute HPLC with UV detection LC-MS
Detector UV absorbance Mass spectrometer: ion source, mass analyzer, ion detector
What it records Signal against time (a chromatogram) Ions sorted by mass-to-charge ratio (m/z)
Main question it answers Purity: the main peak’s share of total peak area Identity: does the observed mass match the theoretical mass?
Identity on its own? Not by retention time alone. ICH Q6A: a single retention time is not regarded as specific Yes for mass. HPLC/MS is named in ICH Q6A as an acceptable combined test
Blind spots A UV peak shows how much, not which molecule Cannot tell Leu from Ile, or D from L forms, by mass alone
Typical COA line Purity, %, by area, with the method named Identity: theoretical vs observed mass, and a match or conforms result

What an identity line on a COA should show

An identity result is only as useful as the detail behind it. Look for:

  • The method. LC-MS or ESI-MS named, not just “MS” or “identity: yes.”
  • The theoretical mass. The value calculated for the labeled sequence, with the kind of mass stated, for example monoisotopic.
  • The observed mass. Either the deconvoluted mass or the observed m/z with its charge state.
  • The criterion and the result. The tolerance applied and a clear match or conforms statement.
  • The lot and the lab. The same lot number as the vial, the lab’s name and a test date.
  • The spectrum, where possible. A printed spectrum lets a reader check the peaks behind the claim.

Our guide to reading a COA walks through the rest of the page, and the peptide testing hub shows how identity fits with the other tests on a lot.

Look up a certificate

Identity by LC-MS Purity by HPLC-UV Search by lot

Enter the lot number printed on the vial to open that lot’s certificate from Freedom Diagnostics. No account is needed. All Vitrapep products are for laboratory research use only, not for human or veterinary use.

Open the COA lookup

How Vitrapep confirms identity

Each Vitrapep lot is sent to Freedom Diagnostics, an independent laboratory, before it is released for sale. Freedom Diagnostics confirms identity by LC-MS and measures purity by HPLC-UV on a sample from that lot. It also measures net content and runs an endotoxin test. The lot’s certificate carries the identity result, the purity figure, the lot number and the test date. You can open it on the certificate lookup page.

A production-lab certificate adds seven more tests, for 11 per lot; the quality page lists them. Every product in the catalog is for laboratory research use only and is not for human or veterinary use.

Frequently asked questions

What is the difference between HPLC and LC-MS?

Both start with a liquid chromatography column. HPLC with a UV detector measures how much material elutes and when, which gives purity. LC-MS sends that material into a mass spectrometer, which measures mass-to-charge ratio and so confirms what the material is.

Can HPLC confirm a peptide’s identity?

Not on its own. ICH Q6A says a single chromatographic retention time is not regarded as specific. A retention-time match also needs a reference standard to compare against.

What does “conforms” mean on an identity line?

That the observed mass fell within the lab’s acceptance criterion for the theoretical mass. A complete certificate shows both masses and the method, not just the word.

Is LC-MS the same as LC-MS/MS?

No. LC-MS/MS adds a second stage that breaks selected ions into fragments and measures those. It is used to confirm sequence, which a single mass measurement cannot do.

What to know now

  • LC-MS: a liquid chromatograph that separates, joined to a mass spectrometer that measures m/z.
  • Identity: observed mass compared with the theoretical mass of the labeled sequence.
  • Purity: HPLC area-%, which says how much, not what.
  • Charge states: one peptide can give several m/z peaks; deconvolution recovers one mass.
  • Limits of mass: no distinction between Leu and Ile, or D and L forms, without further tests.
  • On a COA: method, theoretical mass, observed mass, criterion, result, lot and lab.

What we’re watching

On July 28, 2026, the FDA withdrew its 2021 guidance on generic synthetic peptides that refer to drugs of rDNA origin, saying it no longer reflects the agency’s current scientific thinking. It published 17 revised draft product-specific guidances covering impurity thresholds and related tests, and plans to revise the withdrawn guidance this year. These concern drug products, not research reagents, but they shape how labs characterize peptide impurities.

Also in the library

Sources: United States Pharmacopeia. <736> Mass Spectrometry (general chapter). USP–NF. Rockville; United States Pharmacopeia. <621> Chromatography (general chapter). USP–NF. Rockville; Thermo Fisher Scientific. Overview of Mass Spectrometry for Protein Analysis . Protein Biology Learning Center. https://www.thermofisher.com/us/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/overview-mass-spectrometry.html, Overview of Mass Spectrometry for Protein Analysis; Agilent Technologies 2001, Basics of LC/MS: Primer; Fenn 1989, Science; McCarthy 2023, Pharmaceutical Research; Verlander 2014, BioPharm International; International Council for Harmonisation 1999; D’Hondt 2014, Journal of Pharmaceutical and Biomedical Analysis; U.S. Food and Drug Administration 2026. All 10 citations

Back to the research library

References

  1. United States Pharmacopeia. <736> Mass Spectrometry (general chapter). USP–NF. Rockville, MD: USP. https://doi.org/10.31003/USPNF_M99525_02_01
  2. United States Pharmacopeia. <621> Chromatography (general chapter). USP–NF. Rockville, MD: USP. https://doi.org/10.31003/USPNF_M99380_01_01
  3. Thermo Fisher Scientific. Overview of Mass Spectrometry for Protein Analysis. Protein Biology Learning Center. https://www.thermofisher.com/us/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/overview-mass-spectrometry.html
  4. Agilent Technologies. (2001). Basics of LC/MS: Primer (publication 5988-2045EN). Copy hosted by the Boston University Chemical Instrumentation Center. https://sites.bu.edu/cheminst/files/2021/06/LCMSPrimer.pdf
  5. Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., & Whitehouse, C. M. (1989). Electrospray ionization for mass spectrometry of large biomolecules. Science, 246(4926), 64–71. https://doi.org/10.1126/science.2675315
  6. McCarthy, D., Han, Y., Carrick, K., Schmidt, D., Workman, W., Matejtschuk, P., Duru, C., & Atouf, F. (2023). Reference standards to support quality of synthetic peptide therapeutics. Pharmaceutical Research, 40(6), 1317–1328. https://doi.org/10.1007/s11095-023-03493-1
  7. Verlander, M., & Rode, H. (2014, March 1). Control strategies for synthetic therapeutic peptide APIs, Part I: Analytical consideration. BioPharm International. https://www.biopharminternational.com/view/control-strategies-synthetic-therapeutic-peptide-apis-part-i-analytical-consideration
  8. International Council for Harmonisation. (1999). ICH Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. Step 4 version, 6 October 1999. https://database.ich.org/sites/default/files/Q6A%20Guideline.pdf
  9. D’Hondt, M., Bracke, N., Taevernier, L., Gevaert, B., Verbeke, F., Wynendaele, E., & De Spiegeleer, B. (2014). Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis, 101, 2–30. https://doi.org/10.1016/j.jpba.2014.06.012
  10. U.S. Food and Drug Administration. (2026, July 28). FDA Publishes Revised Draft Product-Specific Guidances for Certain Generic Peptide Products. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-publishes-revised-draft-product-specific-guidances-certain-generic-peptide-products